Table 3.

Influence of potential prognostic factors on bone survival in multivariate analysis

	Stable metastases			Unstable metastases
Factor	Hazard Ratio	95 % CI	p-value	Hazard Ratio	95 % CI	p-value
Age	1.01	0.99–1.02	0.09	1.01	1.00–1.02	0.025
Gender
Female	Reference
Male	1.27	1.01–1.60	0.04	1.07	0.83–1.38	0.59
KPS
> =80 %	Reference
< 80 %	1.27	1.04–1.55	0.02	1.11	0.91–1.35	0.30
Primary site
Breast cancer	Reference
NSCLC	2.77	1.99–3.86	<0.0001	2.00	1.43–2.80	<0.0001
Renal cancer	0.84	0.53–1.33	0.47	0.85	0.54–1.33	0.47
Localization of metastases
Thoracic	Reference
Lumbar	1.07	0.87–1.31	0.53	0.90	0.73–1.11	0.31
Number of metastases
1	Reference
> 1	1.16	0.95–1.41	0.13	1.35	1.11–1.65	0.003
Other distant metastases
Liver yes	Reference
no	0.72	0.56–0.92	0.008	0.71	0.54–0.92	0.003
Brain yes	Reference
no	0.84	0.63–1.11	0.22	0.85	0.63–1.16	0.32
Lung yes	Reference
no	1.27	0.99–1.62	0.06	1.05	0.79–1.40	0.73
Skin yes	Reference
no	1.09	0.69–1.72	0.71	0.91	0.44–1.85	0.79
Bisphosphonates
yes	Reference
no	1.19	0.91–1.56	0.21	1.07	0.79–1.44	0.66
Chemotherapy
yes	Reference
no	0.84	0.68–1.02	0.08	0.97	0.79–1.19	0.79
Orthopedic corset
yes	Reference
no	0.84	0.67–1.06	0.14	0.77	0.62–0.96	0.02
Radiotherapy schedule
> 30 Gy	Reference
< =30 Gy	1.27	0.99–1.63	0.06	1.08	0.86–1.35	0.53

Data in bold p-value <0.05 are significant statistically